comparemela.com

Latest Breaking News On - Minvest partners - Page 2 : comparemela.com

Advisory Services Network LLC Purchases 2,362 Shares of Boston Scientific Co (NYSE:BSX)

Advisory Services Network LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 49,398 shares of the medical equipment provider’s stock after purchasing an additional 2,362 […]

JARISLOWSKY FRASER Ltd Has $175 06 Million Stock Holdings in Boston Scientific Co (NYSE:BSX)

JARISLOWSKY FRASER Ltd trimmed its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,028,215 shares of the medical equipment provider’s stock after selling 56,630 shares during the period. […]

Merus (NASDAQ:MRUS) Reaches New 52-Week High Following Analyst Upgrade

Merus (NASDAQ:MRUS – Get Free Report)’s stock price hit a new 52-week high during trading on Friday after Bank of America raised their price target on the stock from $52.00 to $61.00. Bank of America currently has a buy rating on the stock. Merus traded as high as $57.80 and last traded at $58.00, with […]

Cytokinetics (NASDAQ:CYTK) Price Target Cut to $70 00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective decreased by Raymond James from $92.00 to $70.00 in a research note released on Thursday, Benzinga reports. Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Truist Financial reissued a buy rating and […]

Cytokinetics (NASDAQ:CYTK) Given New $72 00 Price Target at Needham & Company LLC

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently issued reports on CYTK. Mizuho reduced […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.